Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
Cells, Free Full-Text
Darolutamide: New Standard of Care in Nonmetastatic CRPC?
View of Darolutamide (Nubeqa) Canadian Journal of Health
Nubeqa Delays Prostate Cancer Progression in Resistant Prostate
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Cancers, Free Full-Text
ARVib suppresses growth of advanced prostate cancer via inhibition
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate
Prostate Cancer Treatment (PDQ®) - NCI
Focus on Transitional Disease: A Critical Interval to Delay
Abiraterone plus prednisone added to androgen deprivation therapy
Selected Ongoing Trials With Darolutamide In Prostate Cancer
Clinical Development of Darolutamide: A Novel Androgen Receptor
de
por adulto (o preço varia de acordo com o tamanho do grupo)
